Overview
For life sciences, we saw an average of about 460 deals on a quarterly basis, which was up from 2020, at about 405.
-
-
Sub-sector perspectives
We look at life sciences, from a biopharma, diagnostics, biopharma and lab services and medical device, and in healthcare, it's the whole continuum of care.
-
Macro drivers
Inflationary and geopolitical perspectives.
-
Life Sciences perspectives
The life science industry broadly has been extremely active in 2020 and 2021.
-
Healthcare IT
We expect the healthcare IT growth trend to continue.
-
Valuations
An area to more closely gauge in 2022.
-
Healthcare perspectives
Convergence of payers and providers.
